The directed in vivo angiogenesis assay (DIVAA) uses semi-closed small silicone cylinders known as angioreactors. The cylinders are filled with an extracellular matrix such as Geltrex™ that contains the angiogenic or antiangiogenic compound of interest.
Following subcutaneous implantation in nude mice, vascular endothelial cells will migrate into the angioreactors and proliferate to form new blood vessels (if the compound of interest is angiogenic). The angioreactors are designed with a closed end and a fixed surface area so that vessel growth is directed and matrix volume remains constant. Quantification of blood vessel formation is typically accomplished using fluorometric detection. The assay allows accurate and reproducible dose-response analysis and identification of effective doses of factors modulating angiogenesis in vivo. The minimally detectable angiogenic response requires an implantation period of 9 days and approximately 50 ng/ml of angiogenesis factor.¹
This assay demonstrates greater reproducibility than other in vivo assays. The small size of the angioreactor also allows the investigator to conserve samples and implant multiple angioreactors per mouse. While the subcutaneous locale is a practical choice, it is not ideal since angiogenesis does not typically occur in these areas.
- Guedez L, Rivera A, Salloum R et al. (2003). Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol. 162(5):1431-1439.
LT174 updated 7-Oct-2011
For Research Use Only. Not for use in diagnostic procedures.